---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-017680"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2022-01-26T23:59:59+00:00"
generated_at: "2026-06-27T15:32:48.309593+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology appoints Richard Wooster to board of directors; board increases to 8

## Summary
- Richard Wooster, Ph.D., appointed to fill new vacancy, effective Jan. 21, 2022; board expands from 7 to 8.
- Wooster qualifies as independent director; receives option for 29,200 shares vesting over 3 years.
- He brings 30+ years oncology drug discovery experience; discovered BRCA2 gene, co-discovered BRAF mutations.
- Most recently CSO at Translate Bio (acquired by Sanofi 2021); previously VP at GSK.

## SEC filing metadata
- accession: 0001193125-22-017680
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2022-01-26T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/0001193125-22-017680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/d252798d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-017680
- JSON: https://secwatch.observer/filing/0001193125-22-017680.json
- Plain text: https://secwatch.observer/filing/0001193125-22-017680.txt

## Key facts
- Executive change
  Richard Wooster was appointed as Director at ImageneBio, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 21, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Dr. Richard Wooster to fill a newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312522017680/0001193125-22-017680-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.